Compare · OCGN vs OTLK
OCGN vs OTLK
Side-by-side comparison of Ocugen Inc. (OCGN) and Outlook Therapeutics Inc. (OTLK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OCGN and OTLK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- OCGN is the larger of the two at $460.4M, about 2.4x OTLK ($194.7M).
- Over the past year, OCGN is up 34.0% and OTLK is down 35.9% - OCGN leads by 69.9 points.
- OTLK has been more active in the news (4 items in the past 4 weeks vs 3 for OCGN).
- OTLK has more recent analyst coverage (19 ratings vs 9 for OCGN).
- Company
- Ocugen Inc.
- Outlook Therapeutics Inc.
- Price
- $1.36-1.09%
- $1.40-3.79%
- Market cap
- $460.4M
- $194.7M
- 1M return
- +16.24%
- -10.58%
- 1Y return
- +33.99%
- -35.86%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2016
- News (4w)
- 3
- 4
- Recent ratings
- 9
- 19
Ocugen Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Outlook Therapeutics Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Latest OCGN
- Ocugen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
- Ocugen to Participate in Upcoming July Industry Conferences
- Chief Financial Officer Johnson-Greene Treerita Essalima bought $25,830 worth of shares (21,000 units at $1.23), increasing direct ownership by 4% to 521,000 units (SEC Form 4)
- SEC Form 4 filed by Director Kompella Uday
- SEC Form 4 filed by Director Chandrasekhar Satishchandran
- SEC Form 4 filed by Director Castillo Kirsten
- SEC Form 4 filed by Director Zhang Junge
- SEC Form 4 filed by Director Coleman Blaise
- Ocugen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
Latest OTLK
- SEC Form S-3 filed by Outlook Therapeutics Inc.
- Outlook Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Outlook Therapeutics Inc.
- SEC Form 8-K filed by Outlook Therapeutics Inc.
- SEC Form 8-K filed by Outlook Therapeutics Inc.
- Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
- Director Haddadin Yezan Munther bought $24,145 worth of shares (29,000 units at $0.83), increasing direct ownership by 78% to 66,167 units (SEC Form 4)
- Director Sukhtian Ghiath M. bought $5,000,000 worth of shares (8,539,709 units at $0.59) (SEC Form 4)
- SEC Form DEFA14A filed by Outlook Therapeutics Inc.
- SEC Form DEF 14A filed by Outlook Therapeutics Inc.